BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Hepatitis
,
Endothelial cell
,
Metabolism of nitric oxide
,
Clofibrate
,
rs3825942
,
BRAF
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
pd- 1 receptor
NextBio Summary
General Info
Curated Studies
Most Correlated Studies
L1000 CMAP - Hepatocellular carcinoma HEPG2 cells treated with small molecule perturbagens
L1000 CMAP - Breast carcinoma BT20 cells treated with small molecule perturbagens
L1000 CMAP - Breast adenocarcinoma SKBR3 cells treated with small molecule perturbagens
Neural 3D tissue constructs from H1 ESC-derived precursor cells treated with neurotoxic chemicals
L1000 CMAP - Neural progenitor NPC cells treated with small molecule perturbagens
Explore Curated Studies Results
Literature
Most Relevant Literature
Programmed cell death 1 (PD-1) receptor and programmed death ligand 1 (PD-L1) gene expression in pri…
Mechanism of action of PD-1 receptor/ligand targeted cancer immunotherapy.
The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Tre…
Structural basis of HLX10 PD-1 receptor recognition, a promising anti-PD-1 antibody clinical candida…
When is it OK to Stop Anti-Programmed Death 1 Receptor (PD-1) Therapy in Metastatic Melanoma?
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participan…
A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-V…
An Efficacy and Safety Study of a Combination of JNJ-73763989, Nucleos(t)Ide Analogs (NA), and a Pro…
Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced …
A Study of Cetrelimab (JNJ-63723283), a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administe…
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ